Expanding role of beta-blockade in the management of chronic heart failure

Related Experiment Video

Updated: Sep 26, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

J Herbert Patterson1, Jo E Rodgers

  • 1School of Pharmacy, University of North Carolina, CB #7360 Beard Hall, Chapel Hill, NC 27599-7360, USA. hpatterson@unc.edu

Pharmacotherapy
|April 12, 2003
PubMed

Insights

Beta-blockers are crucial for managing heart failure, reversing adverse cardiac remodeling and improving outcomes. Evidence now supports their use in severe heart failure and post-myocardial infarction patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure significantly impacts morbidity and mortality despite treatment advances.
  • Progression involves myocardial reserve decline, reduced exercise tolerance, and altered gene expression.
  • Neurohormonal antagonists, including ACE inhibitors and beta-blockers, are guideline-recommended for reversing cardiac remodeling.

Purpose of the Study:

  • To review the role of beta-blockade in heart failure management.
  • To discuss the expansion of beta-blocker use to severe heart failure and post-myocardial infarction patients.
  • To highlight the impact of individual beta-blocker pharmacology on treatment decisions.

Main Methods:

  • Review of clinical guidelines and randomized clinical trials.
  • Analysis of data supporting beta-blocker efficacy in various heart failure stages.
  • Examination of pharmacological variations among beta-blocking agents.

Main Results:

  • Beta-blockade effectively counteracts chronic adrenergic stimulation's detrimental effects.
  • Initial use was limited to mild-to-moderate heart failure; now expanded to severe cases.
  • Individual agent pharmacology influences treatment choices and ventricular remodeling outcomes.

Conclusions:

  • Beta-blockers are essential for heart failure treatment, improving myocardial function and clinical outcomes.
  • Expanded use in severe heart failure and post-myocardial infarction is supported by clinical data.
  • Understanding agent-specific pharmacology is key for optimizing heart failure management and ventricular remodeling.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...